Teva gets FDA ok for Pfizer's Accupril

Total annual sales of Accupril in the US, including brand and generic, were about $150 million for the year ended June 30, according to IMS sales data.

Teva Pharmaceutical Industries Ltd. said Monday the US Food & Drug Administration had approved its Abbreviated New Drug Application to market a generic of Pfizer Inc.'s Accupril hypertension treatment following the expiration of the pediatric exclusivity for the patent. Total annual sales of Accupril in the US, including brand and generic, were about $150 million for the year ended June 30, according to IMS sales data.